The content on this site is intended for healthcare professionals only
Dr Marshall Posner of the Mount Sinai School of Medicine, NY, talks to ecancertv at ESMO 2010 about various trials for head and neck cancer: The SPECTRUM trial, a phase 3 trial in 600 patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) receiving chemotherapy with or without panitumumab. Also pemetrexed plus cisplatin. He discusses the potential for increased quality of life and advantageous dosing schedules. Dr Posner also discusses his analysis of HPV positive and negative oropharynx patients: 'Five-year survival (OS) and patterns of failure for human papillomavirus (HPV) positive and negative oropharynx cancer (OPC) in the TAX 324 clinical trial.'
Transforming cancer care in India: The Access Cancer Care Initiative
Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer
Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in head and neck cancer treatment in India
Enhancing head and neck oncology: Key insights from the conference
GIST tumours and soft tissue sarcomas
